Condition: Attention Deficit Disorder with Hyperactivity · Diabetes Mellitus, Type 1 · Sponsor: Medical University of Lodz
This clinical trial aims to evaluate the safety and effectiveness of an intervention involving parental training in behaviour management and medication in children with both Type 1 Diabetes (T1D) and Attention Deficit Disorder with Hyperactivity (ADHD). ADHD is a neurodevelopmental disorder that affects around 5% of school-age children and adolescents, while T1D is a chronic disease requiring strict management. After initial parental training provided for parents/legal guardians, the children will be randomized to one of two cross-over groups, and treated with either lisdexamfetamine or methylphenidate first. After dose optimization for first 5-7 weeks, patients will be treated for 6 months total, after which they will be switched to the other drug. Researchers will then compare the ADHD symptom severity as measured by Conners 3 questionnaire, and compare the frequency of any adverse events associated with the therapy. As secondary outcomes, patient's T1D control and quality of life will be compared between the two drugs.
This description comes directly from the study's public registry record.
Agnieszka Butwicka, A/Prof · +46 72 326 66 31 · agnieszka.butwicka@umed.lodz.pl
Arkadiusz Michalak, MD · +48504867777 · arkadiusz.michalak@umed.lodz.pl
Always discuss trial participation with your own doctor first.
| Pediatric Center of the Central Clinical Hospital of the Medical University of Lodz | Lodz, Łódź Voivodeship, Poland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05957055